Clinical Trial Update: Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating neoadjuvant and adjuvant sintilimab combined with chemoradiotherapy versus chemoradiotherapy alone in stage TanyN3M0 nasopharyngea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: First Affiliated Hospital of Guangxi Medical University | Conditions: Nasopharyngeal Carcinoma (NPC) | Phase 2 | Status: NOT_YET_RECRUITING